MedTrace Logo

12 Week Study Of PF-00734200 For The Treatment Of Type 2 Diabetes Mellitus In Subjects Treated With Metformin

NCT00473525 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 303

Last updated 2010-06-24

No results posted yet for this study

Summary

The purpose of this Phase 2a study is to evaluate the efficacy, safety and tolerability, of multiple parallel doses of PF-00734200 following oral administration to adult human subjects with T2DM who currently are on a stable dose of metformin.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Placebo

Placebo QD

DRUG

PF-00734200 10 mg QD

10 mg QD

DRUG

PF-00734200 20 mg QD

20 mg QD

DRUG

PF-00734200 5 mg QD

5 mg QD

DRUG

PF-00734200 2 mg QD

2 mg QD

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • United States
  • Colombia
  • Germany
  • Italy
  • Spain
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00473525 on ClinicalTrials.gov